REBECCA PASTELAK: Open Payments
NPI 1457843872 · DURHAM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,729 in 120 payments from 17 companies in 2025. Trend: 2023 $1,976 · 2024 $2,896 · 2025 $1,729
Food & beverage: $1,729
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $258 |
| Vanda Pharmaceuticals Inc. | 19 | $234 |
| Neurocrine BioSciences, Inc. | 11 | $223 |
| Alkermes, Inc. | 11 | $216 |
| Collegium Pharmaceutical, Inc. | 10 | $147 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $126 |
| Otsuka America Pharmaceutical, Inc. | 6 | $118 |
| Axsome Therapeutics, Inc. | 4 | $70 |
| Lundbeck LLC | 3 | $69 |
| Almatica Pharma LLC | 4 | $66 |
Products named: VRAYLAR, FANAPT, INGREZZA, ARISTADA, Jornay PM, CAPLYTA, ABILIFY ASIMTUFII, REXULTI.
Industry payments across NC — which companies pay providers there.
